Evidence map›Paper›PMID 42745490›Full record

ArticleCancer medicine2026

A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.

Wan-Ling Ho, Ming-Yun Hsieh, Yu-Mei Liao, Shyh-Shin Chiou, Her-Shyong Shiah, Chang-Hsu Chiang, Shiann-Tarng Jou, Hsiu-Ju Yen, Yi-Yen Lee, Muh-Lii Liang and 29 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06853080 (Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06853080 phase2active not recruitingnot on this map

Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors

TypeinterventionalSponsorTaipei Medical UniversityRan2020 to 2025Enrolled6ConditionsAtypical Teratoid/Rhabdoid Tumors (AT/RTs), Central Nervous System (CNS) TumorsArmsBortezomib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Wan-Ling HoDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.ORCID https://orcid.org/0000-0003-1421-0538
Ming-Yun HsiehDepartment of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Yu-Mei LiaoDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Shyh-Shin ChiouDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Her-Shyong ShiahDepartment of Hematology and Oncology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Chang-Hsu ChiangOffice of Human Research, Taipei Medical University, Taipei, Taiwan.
Shiann-Tarng JouDepartment of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan.
Hsiu-Ju YenDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-9606-7354
Yi-Yen LeeDivision of Pediatric Neurosurgery, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Muh-Lii LiangDepartment of Neurosurgery, MacKay Memorial Hospital, Taipei, Taiwan.
Ting-Chi YehDepartment of Medicine, MacKay Medical College, New Taipei City, Taiwan.
Yu-Cheng ChouDepartment of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0002-2359-9883
Fang-Liang HuangDepartment of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Shu-Huey ChenDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Hsin-Lun LeeDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Chia-Chun KuoDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Yi-Shan YangDepartment of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
Shu-Mei ChenDepartment of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
Min-Lan TsaiDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Hsi ChangDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Kevin Li-Chun HsiehDepartment of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chia-Lang FangDepartment of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chia-Yau ChangDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jinn-Li WangDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chu-Chin ChenDepartment of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Joon-Khim LohDivision of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Pei-Chin LinDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0002-3371-3010
Tzu-Chin LinDivision of Neurosurgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Shih-Chung WangDivision of Pediatric Hematology-Oncology, Changhua Christian Children's Hospital, Changhua, Taiwan.ORCID https://orcid.org/0000-0001-7882-7276
Yi-Fang TuDepartment of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.ORCID https://orcid.org/0000-0002-9498-6178
Chao-Neng ChengDepartment of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.ORCID https://orcid.org/0000-0003-3487-9511
Jimmy Ming-Jung ChuangDivision of Neurosurgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0001-5702-9937
Huy Minh TranDepartment of Neurosurgery, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Shian-Ying SungInternational Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Irving LaiGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Kuo-Sheng WuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
James S MiserPediatric Brain Tumor Program, Taipei Cancer Center, Taipei Neurological Institute, Taipei Medical University, Taipei, Taiwan.
Yen-Lin LiuDepartment of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-7571-3123
Tai-Tong WongPediatric Brain Tumor Program, Taipei Cancer Center, Taipei Neurological Institute, Taipei Medical University, Taipei, Taiwan.

Funding

5th National Cancer Control Program MOHW115-TDU-B-222-114013Ministry of EducationNational Science and Technology Council, Taiwan 108-2314-B-038-061-MY3National Science and Technology Council, Taiwan 114-2314-B-038-031-MY3Taipei Medical University Hospital 114TMU-TMUH-20Taipei Municipal Wanfang Hospital IIT-110-19Taiwan Ministry of Health and Welfare Clinical Trial Center MOHW110TDU-B-212-124007TMU Research Center of Cancer Translational Medicine DP2-TMU-115-C-06
6 · The paper itself

Abstract

backgroundAtypical teratoid/rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors that are sensitive to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor, bortezomib, with chemotherapy.

methodsSix patients aged 0.8-13 years with newly diagnosed ATRT were enrolled from January 2022 through December 2023. Bortezomib was given intravenously at the dose of 1.3 mg/m

resultsThirty cycles of bortezomib with chemotherapy were evaluated. No grade 3 or higher toxicities were considered bortezomib-related. Four patients completed 6 cycles of bortezomib; 2 patients discontinued treatment due to progressive disease after 2 and 4 cycles, respectively. An additional 6 cycles of bortezomib were evaluated after high-dose chemotherapy in three patients without grade 4 bortezomib-related toxicity. Five patients had a near-total resection; one patient had a subtotal resection. Four patients were evaluable for response with 2 partial responses, 1 stable disease, and 1 progressive disease. Two patients without measurable tumor after surgery were not evaluable for response. Two patients remain alive without disease at 37 and 40 months, and one patient died without disease at 19 months after diagnosis. Three patients died with progressive disease.

conclusionsThe toxicities were no more than expected with chemotherapy alone. Adding bortezomib to treatment of ATRT is feasible.

trial registrationNCT06853080.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibBrain NeoplasmsRhabdoid TumorTeratomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleProteasome InhibitorsTreatment OutcomeBortezomibProteasome Inhibitorsatypical teratoid/rhabdoid tumor (ATRT)bortezomibchemotherapyfeasibilityproteasome inhibitors

Identifiers

PMID42745490
PMCPMC13578914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.